Dianthus Therapeutics DNTH Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax?
- Dianthus Therapeutics (DNTH) reported other comprehensive income unrealized holding gain loss on securities arising during period net of tax of -$1.06M in Q1 2026.
- How has Dianthus Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax changed year-over-year?
- Dianthus Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax decreased by 748.8% year-over-year, from $164K to -$1.06M.
- What is the long-term trend for Dianthus Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax?
- Over 2 years (2021 to 2023), Dianthus Therapeutics's other comprehensive income unrealized holding gain loss on securities arising during period net of tax has grown at a 445.1% compound annual growth rate (CAGR), from -$7K to $208K.
- What does other comprehensive income unrealized holding gain loss on securities arising during period net of tax mean?
- This metric captures the change in the fair value of investment securities held by the company that have not yet been sold. It represents paper gains or losses on financial assets that are recognized in equity rather than through the income statement. Tracking this provides insight into the volatility and market performance of the company's treasury or investment portfolio.